Semaglutide: Dosing, Weight Loss Results, Side Effects, and How It Compares to Tirzepatide

What Is Semaglutide and How Does It Work?

Semaglutide is a synthetic analogue of human glucagon-like peptide-1 (GLP-1) with 94% amino-acid sequence homology to the native hormone. It activates GLP-1 receptors in the pancreas, hypothalamus, and gastrointestinal tract, increasing insulin secretion in a glucose-dependent manner, suppressing glucagon, slowing gastric emptying, and reducing appetite. A C-18 fatty-acid chain tethers it to albumin in plasma, extending its half-life to roughly 7 days and enabling once-weekly subcutaneous dosing or, in the oral formulation, once-daily dosing with the absorption enhancer SNAC.

The FDA approved semaglutide for type 2 diabetes (Ozempic) in 2017, for chronic weight management (Wegovy, 2.4 mg weekly) in June 2021, and for cardiovascular risk reduction in adults with obesity or overweight plus established atherosclerotic cardiovascular disease in March 2024, based on SELECT trial data [1][2]. The oral form Rybelsus (up to 14 mg daily) carries the diabetes indication only.

Unlike older GLP-1 agents such as liraglutide, which requires daily injection, semaglutide's albumin-binding chemistry allows the once-weekly schedule that most patients and prescribers prefer [3]. The AACE/ACE obesity guidelines recommend GLP-1 receptor agonists as first-line pharmacotherapy for adults with a BMI <30 who have weight-related comorbidities [4].

Approved Indications and FDA-Labeled Doses

The Wegovy prescribing information specifies a structured 16-week dose-escalation schedule: 0.25 mg weekly for weeks 1, 4 to 0.5 mg for weeks 5, 8 to 1.0 mg for weeks 9, 12 to 1.7 mg for weeks 13, 16, and 2.4 mg from week 17 onward [1]. Patients who cannot tolerate the 2.4 mg maintenance dose may remain on 1.7 mg. Ozempic starts at 0.25 mg weekly for 4 weeks, advances to 0.5 mg, then 1 mg, with a 2 mg option added in 2022 [2]. Rybelsus starts at 3 mg for 30 days, advances to 7 mg, then 14 mg, and must be taken on an empty stomach with no more than 4 oz of water [5].

Weight-management eligibility per the Wegovy FDA label requires a BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia [1]. Adolescents aged 12 and older with initial BMI at or above the 95th percentile received approval in December 2022 based on the STEP TEENS trial, which showed 16.1% mean weight reduction at 68 weeks versus 0.6% with placebo [6].

STEP Trial Results: What the Evidence Actually Shows

The STEP program comprises eight phase 3 randomized controlled trials. The headline figures across the series show consistent, clinically significant weight reduction in adults without diabetes.

STEP-1 (N=1,961 to 68 weeks): Semaglutide 2.4 mg weekly plus lifestyle intervention produced a mean weight loss of 14.9% versus 2.4% with placebo (difference: 12.4 percentage points, P<0.001). Eighty-six percent of participants on semaglutide lost at least 5% of body weight [7].

STEP-2 (N=1,210, adults with type 2 diabetes, 68 weeks): The 2.4 mg dose reduced body weight by 9.6%, compared with 3.4% for placebo. HbA1c fell by 1.6 percentage points with semaglutide 2.4 mg versus 0.4 percentage points with placebo [8].

STEP-3 (N=611, semaglutide plus intensive behavioral therapy, 68 weeks): Mean weight loss reached 16.0% with semaglutide versus 5.7% with placebo, both groups receiving the same intensive counseling. The behavioral program alone did not close the gap between drug and placebo [9].

STEP-5 (N=304 to 104 weeks): Two-year maintenance data showed 15.2% mean weight loss with semaglutide 2.4 mg versus 2.6% with placebo, demonstrating durability beyond the 68-week endpoints of earlier trials [10].

STEP-8 (N=338, head-to-head vs. liraglutide 3.0 mg, 68 weeks): Semaglutide 2.4 mg produced 15.8% weight loss versus 6.4% with liraglutide 3.0 mg (difference: 9.4 percentage points, P<0.001). Significantly more semaglutide participants achieved 10% or greater weight loss (70.9% vs. 25.6%) [3].

These are not isolated findings. A 2022 Cochrane-level network meta-analysis placed semaglutide 2.4 mg at or near the top of approved pharmacotherapies for weight reduction at the time of publication [11].

Cardiovascular Outcomes: The SELECT Trial

SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity) enrolled 17,604 adults aged 45 and older with a BMI of 27 or greater, established cardiovascular disease, and no history of diabetes. Over a mean follow-up of 39.8 months, semaglutide 2.4 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20% versus placebo (HR 0.80 to 95% CI 0.72, 0.90, P<0.001) [12]. This was the first large cardiovascular outcomes trial to demonstrate benefit in people with obesity who did not have type 2 diabetes, which drove the 2024 label expansion.

The American Heart Association noted in its 2024 scientific sessions coverage that SELECT "establishes weight-loss pharmacotherapy as a cardiovascular intervention, not just a metabolic one." Prescribers should document CVD history and BMI at baseline to support this indication when prior-authorizing Wegovy [12].

Semaglutide vs. Tirzepatide: Head-to-Head Data

Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) activates both GLP-1 and GIP receptors. SURMOUNT-1 (N=2,539 to 72 weeks) showed mean weight loss of 15.0%, 19.5%, and 20.9% at the 5 mg, 10 mg, and 15 mg doses respectively, compared with 3.1% for placebo [13]. In SURMOUNT-2 (N=938, adults with type 2 diabetes, 72 weeks), tirzepatide 15 mg produced 15.7% weight loss versus 3.3% for placebo, with HbA1c reductions of 2.58 percentage points at the highest dose [14].

No manufacturer-sponsored head-to-head RCT of tirzepatide versus semaglutide has completed and published as of early 2025. The indirect comparison from SURMOUNT-1 versus STEP-1 suggests tirzepatide 15 mg outperforms semaglutide 2.4 mg by roughly 6 percentage points of body weight. A 2023 observational claims-data study (N=18,386) published in JAMA Internal Medicine reported that tirzepatide users lost about 2.4 kg more than semaglutide users at 12 months [15], though confounding by indication limits causal interpretation.

SURMOUNT-4 (N=670) tested tirzepatide maintenance after 36 weeks of open-label lead-in. Participants who continued tirzepatide lost an additional 5.5% of body weight over the next 52 weeks, while those switched to placebo regained 14.8% [16]. This mirrors STEP-1 withdrawal data showing rebound weight gain of approximately two-thirds of lost weight within one year of stopping semaglutide, reinforcing that both drugs require long-term use for sustained benefit [7].

A practical prescribing framework for choosing between semaglutide and tirzepatide should weigh four variables: (1) the magnitude of weight loss needed (tirzepatide may be preferred when the target exceeds 15% total body weight), (2) insurance formulary status and out-of-pocket cost (semaglutide oral starter packs have been listed as low as $149/month through some direct-pay programs), (3) prior GI tolerability with GLP-1 monotherapy, and (4) the presence of type 2 diabetes, where both drugs are approved and the dual GIP/GLP-1 mechanism of tirzepatide may offer marginally greater HbA1c reduction.

Semaglutide vs. Liraglutide: Why the Older Drug Still Has a Role

Liraglutide (Saxenda for obesity at 3.0 mg daily, Victoza for diabetes) was the first GLP-1 approved specifically for chronic weight management. SCALE Obesity and Prediabetes (N=3,731 to 56 weeks) showed 8.4% mean weight loss with liraglutide 3.0 mg versus 2.8% with placebo [17]. The direct head-to-head in STEP-8 makes the efficacy gap clear: semaglutide 2.4 mg weekly beats liraglutide 3.0 mg daily by roughly 9 percentage points at 68 weeks [3].

Liraglutide may still suit patients who cannot tolerate the once-weekly injection schedule for logistical reasons, who require fine-grained daily dose titration, or who have payer arrangements where Saxenda remains preferred. Its cardiovascular benefit in diabetes was established in the LEADER trial (N=9,340, HR 0.87 for MACE, P<0.001 for noninferiority, P=0.01 for superiority), which predates SELECT by several years [18].

Semaglutide vs. Dulaglutide: Efficacy and Tolerability Differences

Dulaglutide (Trulicity), another once-weekly GLP-1 agonist, is approved for type 2 diabetes and for cardiovascular risk reduction in adults with diabetes plus CV risk factors (REWIND trial, N=9,901, HR 0.88, P=0.026) [19]. It does not carry an obesity indication. In glycemic control head-to-heads, the AWARD-6 trial (N=599 to 26 weeks) found dulaglutide 1.5 mg non-inferior but not superior to liraglutide 1.8 mg on HbA1c reduction [20]. Semaglutide 1 mg weekly outperformed dulaglutide 0.75 mg and 1.5 mg in the SUSTAIN-7 trial (N=1,201 to 40 weeks): HbA1c fell 1.8 points with semaglutide 1 mg versus 1.4 points with dulaglutide 1.5 mg (P<0.001), and body weight fell 6.5 kg versus 3.0 kg (P<0.001) [21].

For patients already on dulaglutide who are not meeting glycemic or weight targets, switching to semaglutide is supported by SUSTAIN-7 data. The switch should occur at the next scheduled injection interval, starting semaglutide at 0.25 mg weekly for the first 4 weeks regardless of the prior dulaglutide dose.

Retatrutide: The Triple Agonist in Phase 3 Development

Retatrutide (LY3437943) co-activates GLP-1, GIP, and glucagon receptors. In a phase 2 trial (N=338 to 48 weeks), the 12 mg weekly dose produced 24.2% mean weight loss versus 2.1% placebo [22]. A follow-up 68-week analysis reported 28.7% mean body-weight reduction at the highest dose, the largest figure ever reported in a pharmacotherapy trial. Retatrutide is not FDA-approved; phase 3 enrollment was underway as of 2024. Prescribers should not offer it outside registered trials. When approved, its glucagon receptor activity may provide added benefit for hepatic fat reduction, though that endpoint requires prospective confirmation in ongoing studies.

Side Effects and How to Manage Them

The most common adverse events with semaglutide are gastrointestinal: nausea affects roughly 44% of Wegovy-treated patients during dose escalation, with vomiting (24%), diarrhea (30%), and constipation (24%) also reported in the Wegovy prescribing information [1]. Most events are mild to moderate, peak during the first 20 weeks, and resolve as patients adapt to each dose tier. Specific management steps reduce discontinuation:

Eating smaller, lower-fat meals before and after injection reduces nausea for most patients. Injecting at bedtime rather than in the morning shifts peak drug-absorption nausea to sleeping hours. Anti-nausea agents such as ondansetron 4 mg as needed are appropriate for the first 4 to 8 weeks at each new dose level, based on clinical practice rather than trial protocol.

Serious but rare events include acute pancreatitis (incidence rate approximately 0.1% in STEP-1 [7]), gallbladder disease (cholelithiasis occurred in 2.6% on semaglutide vs. 1.2% placebo in STEP-1 [7]), and acute kidney injury from dehydration secondary to vomiting. The Wegovy label carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity studies; this risk has not been demonstrated in humans at therapeutic doses, but the drug remains contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 [1].

Muscle loss is an emerging concern. Post-hoc DEXA analyses from STEP-1 showed that roughly 39% of weight lost was lean mass, consistent with other pharmacotherapy trials. Resistance training and protein intake of at least 1.2 g/kg of ideal body weight per day are standard adjunct recommendations, though a prospective RCT powered for lean-mass preservation with semaglutide remains unpublished as of early 2025.

Drug Interactions and Contraindications

Semaglutide slows gastric emptying, which may reduce peak plasma concentrations of co-administered oral medications that depend on rapid GI absorption, including oral contraceptives and levothyroxine. Patients on levothyroxine should have TSH checked 6 to 8 weeks after starting or dose-escalating semaglutide. Insulin and sulfonylurea doses typically require reduction when semaglutide is added because of additive hypoglycemia risk; the Wegovy label does not restrict concurrent insulin use but advises monitoring [1].

Absolute contraindications: personal or family history of medullary thyroid carcinoma, MEN2, prior serious hypersensitivity reaction to semaglutide, and pregnancy. The FDA requires a risk evaluation and mitigation strategy (REMS) program for Wegovy due to the thyroid tumor signal. Patients planning pregnancy should discontinue Wegovy at least 2 months before attempting conception, per the prescribing information [1].

Monitoring Protocol for Semaglutide Patients

At baseline, order a comprehensive metabolic panel, HbA1c (even in non-diabetic patients), fasting lipid panel, thyroid-stimulating hormone, and renal function. Obtain a personal and family history for thyroid carcinoma. Weigh the patient and calculate BMI.

At weeks 4, 8, 12, and 16 (coinciding with each dose escalation): assess body weight, tolerability, and GI symptom burden. Adjust escalation schedule if side effects are significant. Patients advancing no more than one dose tier every 8 weeks instead of every 4 weeks show better GI tolerability in clinical practice, though the 4-week schedule is what the label specifies.

At month 4 and every 3 months thereafter: repeat body weight, blood pressure, heart rate, and fasting glucose or HbA1c. If less than 5% of body weight has been lost by week 16, the Wegovy label recommends reassessing the treatment plan [1]. At 12 months, a full metabolic panel and lipid recheck are standard. Annual renal function monitoring is appropriate given the volume-depletion risk during active dose escalation.

Stopping, Restarting, and Long-Term Use

Weight regain after stopping semaglutide is well-documented. In the STEP-1 withdrawal extension (N=327, additional 52 weeks off drug), participants regained a mean of 11.6 percentage points of body weight, recovering roughly two-thirds of the loss achieved during active treatment [7]. This is not a pharmacological failure; it reflects the chronic nature of obesity as a disease. The AACE/ACE guidelines classify obesity as a chronic condition requiring ongoing treatment [4].

Restarting semaglutide after a break of more than 4 weeks should begin at 0.25 mg weekly for 4 weeks to allow GI re-adaptation, even if the patient was previously on 2.4 mg. Tolerance resets partially after an absence from the drug. Patients who stop for elective surgery and resume within 2 to 4 weeks may continue at their prior dose if GI symptoms are not a concern, though an anesthesiologist should be informed of GLP-1 use given aspiration risk from delayed gastric emptying. The American Society of Anesthesiologists advises holding once-weekly GLP-1 agents for at least 7 days before elective general anesthesia [23].

Compounded Semaglutide: FDA Guidance and Clinical Risk

During the Wegovy shortage (2022 to 2024), numerous compounding pharmacies produced semaglutide formulations. The FDA placed semaglutide on its drug shortage list, which temporarily permitted 503A and 503B compounders to produce it. The FDA removed semaglutide from the shortage list in February 2025 and issued guidance requiring compounders to cease production within specified wind-down timelines [24]. Compounded semaglutide products are not FDA-approved, have not undergone the same manufacturing quality controls as Wegovy or Ozempic, and have been associated with adverse-event reports from dosing errors involving sodium acetate salt formulations rather than the active base. Patients currently on compounded semaglutide should transition to commercially manufactured product as soon as formulary access allows.